FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib

Web Exclusives - FDA Updates, In the News, Lung Cancer, Thyroid Cancer

On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020.

Previously, the FDA granted breakthrough therapy and orphan drug designations for selpercatinib to treat certain patients with advanced RET fusion-positive thyroid cancer and those with RET-altered NSCLC or MTC. The agent was also granted orphan drug designation by the FDA for the treatment of patients with RET fusion-positive NSCLC, RET-mutant MTC, and RET fusion-positive thyroid cancer.

“We are pleased the FDA granted priority review status for the NDA for selpercatinib. This represents an important step toward providing a new precision therapy for people living with certain RET-driven cancers,” stated Anne E. White, President, Lilly Oncology, in a company press release.

Key Takeaways:

  • The NDA includes data from the phase 1/2 LIBRETTO-001 clinical trial, the largest study of patients with RET-driven lung and thyroid cancers treated with an RET inhibitor. Data from phase 2 of the study showed an overall response rate (ORR) of 77% in evaluable patients with RET fusion-positive cancers. In 2019, updated data showed an ORR of 68% in patients with lung cancer and an ORR of 56% in patients with thyroid cancer.
  • RET fusions have been identified in approximately 2% of NSCLC, 10% to 20% of papillary and other thyroid cancers, and a subset of other cancers. Activating RET point mutations account for approximately 60% of MTC. RET fusion cancers and RET-mutant MTC depend on this single activated kinase for their uncontrolled growth.
  • In December 2019, Lilly Oncology opened 2 phase 3 trials: LIBRETTO-431, which will evaluate selpercatinib in treatment-naïve patients with RET fusion-positive NSCLC, and LIBRETTO-531, which will evaluate selpercatinib in treatment-naïve patients with RET-mutant MTC. Each trial will enroll 400 patients.
Related Items
Metastatic Non–Small-Cell Lung Cancer
David Spigel, MD
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
Nonmetastatic Non–Small-Cell Lung Cancer
Geoff Oxnard, MD
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
Small-Cell Lung Cancer and Mesothelioma
David Spigel, MD
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
Metastatic Non–Small-Cell Lung Cancer with Targetable Mutations
Geoff Oxnard, MD
2020 Year in Review - Lung Cancer published on January 20, 2021 in Lung Cancer
Durvalumab in Combination with Chemotherapy as First-Line Treatment for Extensive-Stage SCLC (CASPIAN Data)
2020 Year in Review - Lung Cancer published on December 2, 2020 in Lung Cancer
Platinum Doublet Chemotherapy plus Pembrolizumab for Patients with SCLC: KEYNOTE-604
2020 Year in Review - Lung Cancer published on December 2, 2020 in Lung Cancer
Cediranib Combined with Olaparib in Patients with Platinum-Pretreated SCLC
2020 Year in Review - Lung Cancer published on December 2, 2020 in Lung Cancer
Lurbinectedin for Second-Line Treatment of Patients with Metastatic SCLC
2020 Year in Review - Lung Cancer published on December 2, 2020 in Lung Cancer
Real-World Data for Nivolumab in Patients with Malignant Mesothelioma
2020 Year in Review - Lung Cancer published on December 2, 2020 in Lung Cancer
Trastuzumab Deruxtecan in Patients with HER2-Mutated Advanced NSCLC
2020 Year in Review - Lung Cancer published on December 2, 2020 in Lung Cancer
Last modified: April 27, 2020